nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralidoxime—Inflammation—Estropipate—osteoporosis	0.036	0.0369	CcSEcCtD
Pralidoxime—Inflammation—Ibandronate—osteoporosis	0.0345	0.0354	CcSEcCtD
Pralidoxime—Inflammation—Risedronate—osteoporosis	0.0284	0.0292	CcSEcCtD
Pralidoxime—Inflammation—Pamidronate—osteoporosis	0.027	0.0277	CcSEcCtD
Pralidoxime—Inflammation—Zoledronate—osteoporosis	0.0247	0.0253	CcSEcCtD
Pralidoxime—Inflammation—Conjugated Estrogens—osteoporosis	0.0238	0.0244	CcSEcCtD
Pralidoxime—Inflammation—Estradiol—osteoporosis	0.019	0.0195	CcSEcCtD
Pralidoxime—Pain—Calcium Acetate—osteoporosis	0.0188	0.0192	CcSEcCtD
Pralidoxime—Drowsiness—Calcitriol—osteoporosis	0.0183	0.0188	CcSEcCtD
Pralidoxime—Muscular weakness—Risedronate—osteoporosis	0.0177	0.0181	CcSEcCtD
Pralidoxime—Haemoglobin—Alendronate—osteoporosis	0.0174	0.0178	CcSEcCtD
Pralidoxime—Haemorrhage—Alendronate—osteoporosis	0.0173	0.0177	CcSEcCtD
Pralidoxime—Haemoglobin—Ibandronate—osteoporosis	0.0169	0.0173	CcSEcCtD
Pralidoxime—Haemorrhage—Ibandronate—osteoporosis	0.0168	0.0172	CcSEcCtD
Pralidoxime—Pain—Ergocalciferol—osteoporosis	0.0166	0.017	CcSEcCtD
Pralidoxime—Haemoglobin—Calcitriol—osteoporosis	0.0165	0.017	CcSEcCtD
Pralidoxime—Haemorrhage—Calcitriol—osteoporosis	0.0165	0.0169	CcSEcCtD
Pralidoxime—Muscular weakness—Zoledronate—osteoporosis	0.0153	0.0157	CcSEcCtD
Pralidoxime—Dizziness—Calcium Acetate—osteoporosis	0.0145	0.0149	CcSEcCtD
Pralidoxime—Haemoglobin—Ethinyl Estradiol—osteoporosis	0.0143	0.0146	CcSEcCtD
Pralidoxime—Haemorrhage—Ethinyl Estradiol—osteoporosis	0.0142	0.0146	CcSEcCtD
Pralidoxime—Haemoglobin—Risedronate—osteoporosis	0.0139	0.0143	CcSEcCtD
Pralidoxime—Haemorrhage—Risedronate—osteoporosis	0.0139	0.0142	CcSEcCtD
Pralidoxime—Haemoglobin—Pamidronate—osteoporosis	0.0132	0.0136	CcSEcCtD
Pralidoxime—Haemorrhage—Pamidronate—osteoporosis	0.0132	0.0135	CcSEcCtD
Pralidoxime—Agitation—Calcitriol—osteoporosis	0.0132	0.0135	CcSEcCtD
Pralidoxime—Nausea—Calcium Acetate—osteoporosis	0.013	0.0134	CcSEcCtD
Pralidoxime—Nausea—Ergocalciferol—osteoporosis	0.0115	0.0118	CcSEcCtD
Pralidoxime—Somnolence—Estropipate—osteoporosis	0.0111	0.0114	CcSEcCtD
Pralidoxime—Pain—Estropipate—osteoporosis	0.0107	0.0109	CcSEcCtD
Pralidoxime—Agitation—Pamidronate—osteoporosis	0.0105	0.0108	CcSEcCtD
Pralidoxime—Pain—Alendronate—osteoporosis	0.0105	0.0108	CcSEcCtD
Pralidoxime—Somnolence—Calcitriol—osteoporosis	0.0104	0.0107	CcSEcCtD
Pralidoxime—Pain—Raloxifene—osteoporosis	0.0103	0.0106	CcSEcCtD
Pralidoxime—Pain—Ibandronate—osteoporosis	0.0102	0.0105	CcSEcCtD
Pralidoxime—Pain—Calcitriol—osteoporosis	0.01	0.0103	CcSEcCtD
Pralidoxime—Vision blurred—Zoledronate—osteoporosis	0.00987	0.0101	CcSEcCtD
Pralidoxime—Agitation—Zoledronate—osteoporosis	0.00962	0.00987	CcSEcCtD
Pralidoxime—Vision blurred—Conjugated Estrogens—osteoporosis	0.0095	0.00975	CcSEcCtD
Pralidoxime—Haemoglobin—Estradiol—osteoporosis	0.00932	0.00956	CcSEcCtD
Pralidoxime—Haemorrhage—Estradiol—osteoporosis	0.00927	0.00951	CcSEcCtD
Pralidoxime—Tachycardia—Pamidronate—osteoporosis	0.00913	0.00937	CcSEcCtD
Pralidoxime—Headache—Etidronic acid—osteoporosis	0.00902	0.00925	CcSEcCtD
Pralidoxime—Nausea—Etidronic acid—osteoporosis	0.00855	0.00877	CcSEcCtD
Pralidoxime—Pain—Risedronate—osteoporosis	0.00842	0.00863	CcSEcCtD
Pralidoxime—Tachycardia—Zoledronate—osteoporosis	0.00834	0.00855	CcSEcCtD
Pralidoxime—Somnolence—Pamidronate—osteoporosis	0.00832	0.00853	CcSEcCtD
Pralidoxime—Dizziness—Estropipate—osteoporosis	0.00824	0.00845	CcSEcCtD
Pralidoxime—Dizziness—Alendronate—osteoporosis	0.00811	0.00832	CcSEcCtD
Pralidoxime—Tachycardia—Conjugated Estrogens—osteoporosis	0.00803	0.00824	CcSEcCtD
Pralidoxime—Pain—Pamidronate—osteoporosis	0.008	0.00821	CcSEcCtD
Pralidoxime—Dizziness—Raloxifene—osteoporosis	0.00798	0.00818	CcSEcCtD
Pralidoxime—Dizziness—Ibandronate—osteoporosis	0.0079	0.0081	CcSEcCtD
Pralidoxime—Headache—Estropipate—osteoporosis	0.0078	0.008	CcSEcCtD
Pralidoxime—Headache—Alendronate—osteoporosis	0.00768	0.00788	CcSEcCtD
Pralidoxime—Somnolence—Zoledronate—osteoporosis	0.0076	0.00779	CcSEcCtD
Pralidoxime—Headache—Raloxifene—osteoporosis	0.00756	0.00775	CcSEcCtD
Pralidoxime—Headache—Ibandronate—osteoporosis	0.00748	0.00767	CcSEcCtD
Pralidoxime—Agitation—Estradiol—osteoporosis	0.00742	0.00761	CcSEcCtD
Pralidoxime—Nausea—Estropipate—osteoporosis	0.0074	0.00759	CcSEcCtD
Pralidoxime—Headache—Calcitriol—osteoporosis	0.00732	0.00751	CcSEcCtD
Pralidoxime—Somnolence—Conjugated Estrogens—osteoporosis	0.00732	0.0075	CcSEcCtD
Pralidoxime—Pain—Zoledronate—osteoporosis	0.00731	0.0075	CcSEcCtD
Pralidoxime—Nausea—Alendronate—osteoporosis	0.00729	0.00747	CcSEcCtD
Pralidoxime—Nausea—Raloxifene—osteoporosis	0.00717	0.00735	CcSEcCtD
Pralidoxime—Nausea—Ibandronate—osteoporosis	0.00709	0.00728	CcSEcCtD
Pralidoxime—Pain—Conjugated Estrogens—osteoporosis	0.00704	0.00722	CcSEcCtD
Pralidoxime—Nausea—Calcitriol—osteoporosis	0.00694	0.00712	CcSEcCtD
Pralidoxime—Dizziness—Ethinyl Estradiol—osteoporosis	0.00668	0.00685	CcSEcCtD
Pralidoxime—Dizziness—Risedronate—osteoporosis	0.00651	0.00668	CcSEcCtD
Pralidoxime—Tachycardia—Estradiol—osteoporosis	0.00643	0.00659	CcSEcCtD
Pralidoxime—Headache—Ethinyl Estradiol—osteoporosis	0.00632	0.00649	CcSEcCtD
Pralidoxime—Dizziness—Pamidronate—osteoporosis	0.00619	0.00635	CcSEcCtD
Pralidoxime—Headache—Risedronate—osteoporosis	0.00617	0.00632	CcSEcCtD
Pralidoxime—Nausea—Ethinyl Estradiol—osteoporosis	0.006	0.00615	CcSEcCtD
Pralidoxime—Headache—Pamidronate—osteoporosis	0.00586	0.00601	CcSEcCtD
Pralidoxime—Somnolence—Estradiol—osteoporosis	0.00586	0.00601	CcSEcCtD
Pralidoxime—Nausea—Risedronate—osteoporosis	0.00585	0.006	CcSEcCtD
Pralidoxime—Dizziness—Zoledronate—osteoporosis	0.00565	0.0058	CcSEcCtD
Pralidoxime—Pain—Estradiol—osteoporosis	0.00563	0.00578	CcSEcCtD
Pralidoxime—Nausea—Pamidronate—osteoporosis	0.00556	0.0057	CcSEcCtD
Pralidoxime—Dizziness—Conjugated Estrogens—osteoporosis	0.00544	0.00558	CcSEcCtD
Pralidoxime—Headache—Zoledronate—osteoporosis	0.00535	0.00549	CcSEcCtD
Pralidoxime—Headache—Conjugated Estrogens—osteoporosis	0.00516	0.00529	CcSEcCtD
Pralidoxime—Nausea—Zoledronate—osteoporosis	0.00508	0.00521	CcSEcCtD
Pralidoxime—Nausea—Conjugated Estrogens—osteoporosis	0.00489	0.00501	CcSEcCtD
Pralidoxime—Dizziness—Estradiol—osteoporosis	0.00436	0.00447	CcSEcCtD
Pralidoxime—Headache—Estradiol—osteoporosis	0.00413	0.00423	CcSEcCtD
Pralidoxime—Nausea—Estradiol—osteoporosis	0.00391	0.00401	CcSEcCtD
Pralidoxime—ACHE—Monoamine Transport—TNFRSF11B—osteoporosis	0.00149	0.0595	CbGpPWpGaD
Pralidoxime—ACHE—Synthesis, secretion, and deacylation of Ghrelin—LEP—osteoporosis	0.00112	0.045	CbGpPWpGaD
Pralidoxime—ACHE—Glycerophospholipid biosynthesis—MGLL—osteoporosis	0.00103	0.0411	CbGpPWpGaD
Pralidoxime—BCHE—Synthesis, secretion, and deacylation of Ghrelin—LEP—osteoporosis	0.001	0.0402	CbGpPWpGaD
Pralidoxime—ACHE—Synthesis, secretion, and deacylation of Ghrelin—IGF1—osteoporosis	0.000929	0.0372	CbGpPWpGaD
Pralidoxime—BCHE—Glycerophospholipid biosynthesis—MGLL—osteoporosis	0.000917	0.0367	CbGpPWpGaD
Pralidoxime—BCHE—Synthesis, secretion, and deacylation of Ghrelin—IGF1—osteoporosis	0.000829	0.0332	CbGpPWpGaD
Pralidoxime—ACHE—Peptide hormone metabolism—REN—osteoporosis	0.000801	0.032	CbGpPWpGaD
Pralidoxime—ACHE—Phospholipid metabolism—MGLL—osteoporosis	0.000717	0.0287	CbGpPWpGaD
Pralidoxime—BCHE—Peptide hormone metabolism—REN—osteoporosis	0.000714	0.0286	CbGpPWpGaD
Pralidoxime—BCHE—Phospholipid metabolism—MGLL—osteoporosis	0.00064	0.0256	CbGpPWpGaD
Pralidoxime—ACHE—Peptide hormone metabolism—ACE—osteoporosis	0.0005	0.02	CbGpPWpGaD
Pralidoxime—BCHE—Peptide hormone metabolism—ACE—osteoporosis	0.000446	0.0178	CbGpPWpGaD
Pralidoxime—ACHE—Monoamine Transport—IL1B—osteoporosis	0.000432	0.0173	CbGpPWpGaD
Pralidoxime—ACHE—ATF-2 transcription factor network—ESR1—osteoporosis	0.000397	0.0159	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.000359	0.0144	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000321	0.0129	CbGpPWpGaD
Pralidoxime—ACHE—Monoamine Transport—TNF—osteoporosis	0.000314	0.0126	CbGpPWpGaD
Pralidoxime—ACHE—Peptide hormone metabolism—LEP—osteoporosis	0.00031	0.0124	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000305	0.0122	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000287	0.0115	CbGpPWpGaD
Pralidoxime—BCHE—Peptide hormone metabolism—LEP—osteoporosis	0.000277	0.0111	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000272	0.0109	CbGpPWpGaD
Pralidoxime—ACHE—Peptide hormone metabolism—POMC—osteoporosis	0.000267	0.0107	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—CCT2—osteoporosis	0.000263	0.0105	CbGpPWpGaD
Pralidoxime—ACHE—Peptide hormone metabolism—IGF1—osteoporosis	0.000256	0.0103	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	0.000256	0.0102	CbGpPWpGaD
Pralidoxime—BCHE—Peptide hormone metabolism—POMC—osteoporosis	0.000238	0.00952	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000237	0.00948	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—CCT2—osteoporosis	0.000235	0.0094	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000231	0.00924	CbGpPWpGaD
Pralidoxime—BCHE—Peptide hormone metabolism—IGF1—osteoporosis	0.000229	0.00916	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—TUBA1B—osteoporosis	0.000224	0.00896	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000211	0.00846	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000206	0.00824	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—TUBA1B—osteoporosis	0.0002	0.00799	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000185	0.00738	CbGpPWpGaD
Pralidoxime—ACHE—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000183	0.00732	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—RPL24—osteoporosis	0.000179	0.00716	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000165	0.00659	CbGpPWpGaD
Pralidoxime—BCHE—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000163	0.00653	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—RPL24—osteoporosis	0.00016	0.00639	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—TLN1—osteoporosis	0.000157	0.00629	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000157	0.00628	CbGpPWpGaD
Pralidoxime—ACHE—ATF-2 transcription factor network—IL6—osteoporosis	0.000155	0.00621	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	0.000155	0.0062	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—REN—osteoporosis	0.000151	0.00605	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—PKM—osteoporosis	0.000143	0.00573	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—FDPS—osteoporosis	0.000143	0.00573	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—TLN1—osteoporosis	0.00014	0.00561	CbGpPWpGaD
Pralidoxime—ACHE—Neuronal System—ADCY5—osteoporosis	0.00014	0.00561	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.00014	0.0056	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—GPD2—osteoporosis	0.000136	0.00543	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—PGLS—osteoporosis	0.000136	0.00543	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—REN—osteoporosis	0.000135	0.0054	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	0.000134	0.00537	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—PKM—osteoporosis	0.000128	0.00511	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—FDPS—osteoporosis	0.000128	0.00511	CbGpPWpGaD
Pralidoxime—BCHE—Neuronal System—ADCY5—osteoporosis	0.000125	0.005	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—ATIC—osteoporosis	0.000124	0.00496	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—PNP—osteoporosis	0.000124	0.00496	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—PGLS—osteoporosis	0.000121	0.00484	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—GPD2—osteoporosis	0.000121	0.00484	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—ATIC—osteoporosis	0.000111	0.00443	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—PNP—osteoporosis	0.000111	0.00443	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—OXCT1—osteoporosis	0.000105	0.00422	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—CA2—osteoporosis	0.000105	0.00422	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—MGLL—osteoporosis	0.000103	0.00411	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	9.69e-05	0.00388	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—ACE—osteoporosis	9.43e-05	0.00378	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—CA2—osteoporosis	9.41e-05	0.00377	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—OXCT1—osteoporosis	9.41e-05	0.00377	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—MGLL—osteoporosis	9.17e-05	0.00367	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—IDH2—osteoporosis	8.74e-05	0.0035	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	8.65e-05	0.00346	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—ACE—osteoporosis	8.42e-05	0.00337	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—CYP27A1—osteoporosis	8.22e-05	0.00329	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	8.06e-05	0.00323	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	8.05e-05	0.00322	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—ACP5—osteoporosis	7.99e-05	0.0032	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	7.89e-05	0.00316	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—IDH2—osteoporosis	7.8e-05	0.00312	CbGpPWpGaD
Pralidoxime—ACHE—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	7.51e-05	0.00301	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—TPI1—osteoporosis	7.43e-05	0.00297	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—CYP27A1—osteoporosis	7.33e-05	0.00293	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—ACP5—osteoporosis	7.13e-05	0.00285	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	7.04e-05	0.00282	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—P4HB—osteoporosis	6.99e-05	0.0028	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—GAPDH—osteoporosis	6.86e-05	0.00274	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—RAP1A—osteoporosis	6.68e-05	0.00267	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—TPI1—osteoporosis	6.63e-05	0.00265	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—P4HB—osteoporosis	6.23e-05	0.00249	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—GAPDH—osteoporosis	6.12e-05	0.00245	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—RAP1A—osteoporosis	5.96e-05	0.00238	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—LEP—osteoporosis	5.86e-05	0.00234	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.83e-05	0.00233	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—ENO1—osteoporosis	5.4e-05	0.00216	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—PSMA2—osteoporosis	5.32e-05	0.00213	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—PSMA5—osteoporosis	5.32e-05	0.00213	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—LEP—osteoporosis	5.23e-05	0.00209	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.2e-05	0.00208	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—POMC—osteoporosis	5.03e-05	0.00201	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism of proteins—IGF1—osteoporosis	4.84e-05	0.00194	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—ENO1—osteoporosis	4.82e-05	0.00193	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—PSMA2—osteoporosis	4.75e-05	0.0019	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—PSMA5—osteoporosis	4.75e-05	0.0019	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—POMC—osteoporosis	4.49e-05	0.0018	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism of proteins—IGF1—osteoporosis	4.32e-05	0.00173	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—CYP19A1—osteoporosis	4.32e-05	0.00173	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—CYP19A1—osteoporosis	3.85e-05	0.00154	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—ADCY5—osteoporosis	3.53e-05	0.00141	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—GPX1—osteoporosis	3.52e-05	0.00141	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—MTHFR—osteoporosis	3.24e-05	0.0013	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—ADCY5—osteoporosis	3.15e-05	0.00126	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—GPX1—osteoporosis	3.14e-05	0.00125	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—MTHFR—osteoporosis	2.89e-05	0.00116	CbGpPWpGaD
Pralidoxime—ACHE—Metabolism—POMC—osteoporosis	2.59e-05	0.00104	CbGpPWpGaD
Pralidoxime—BCHE—Metabolism—POMC—osteoporosis	2.31e-05	0.000926	CbGpPWpGaD
